Tempest
Overview
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer treatments through first-in-class targeted and immune-mediated therapeutics. Headquartered in Brisbane, California, the company was founded to advance therapies targeting tumor-specific and immune-related mechanisms. Tempest is notably working on small molecule product candidates targeting a diverse array of tumors. The company has raised substantial funds through various financing rounds to support its research and development programs, although specific figures relating to total raised capital and their founding date require consultation from recent sources.
Recent Developments
- November 2024: Tempest received FDA's "Study May Proceed" letter for a pivotal Phase 3 trial of amezalpat in first-line hepatocellular carcinoma (HCC) treatment. This approval marks a significant milestone towards the clinical advancement of their TPST-1120 compound.
- August 2024: Tempest Therapeutics reported additional positive survival data for amezalpat, showing a six-month improvement in median survival for HCC patients over the control group. The data sustain a consistent 0.65 hazard ratio, which aligns with previous analyses.
- July 2024: Plans were outlined to advance TPST-1495 into a Phase 2 study targeting Familial Adenomatous Polyposis, supported by the National Cancer Institute's Division of Cancer Prevention.
- March 2024: They presented data at the Society for Immunotherapy of Cancer annual meeting, outlining the effectiveness of TPST-1120 in reducing kidney cancer growth when applied with frontline chemotherapy and immunotherapy.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | Not specified |
| Headquarters | Brisbane, California, USA |
| Founders | Not specified |
| Revenue | Not publicly declared |
| Profits | Not publicly declared |
| Key Investors | Not specified |
| Industry | Biotechnology |
| Number of Employees | Not specified |
Early History
Tempest Therapeutics emerged from a need to address challenging cancers through novel immune-mediated and targeted therapies. Initially operating under the ambitious goal of tackling complex tumor environments, Tempest rapidly developed its research and development capabilities. A pivotal moment in its formative years was the establishment of partnerships with leading pharmaceutical companies and research institutions to bolster its nascent pipeline. This strategy facilitated the early development of innovative cancer drugs, drawing significant interest from investors keen on the burgeoning field of cancer immunotherapy.
Company Profile and Achievements
- Tempest's core strategy focuses on discovering and advancing small molecule therapies that can offer selective cancer treatment mechanisms.
- 2019: Achieved significant progress with TPST-1120 and TPST-1495, targeting PPARα and dual EP2/4 prostaglandin receptors, respectively.
- 2021: Formalized a strategic collaboration with Roche to advance a TPST-1120 study in first-line HCC.
- Secured a firm reputation in the clinical trials domain, positioning its products for potential pivotal Phase 3 studies.
- Gained recognition for its innovative approach to combining immune checkpoint blockade with metabolic pathway inhibition, particularly in PD-1 inhibitor-refractory cases.
Current Operations and Market Position
Tempest is actively pursuing the development of its core pipeline assets into advanced clinical stages. Their strategic focus remains on TPST-1120 for hepatocellular carcinoma, with plans to establish it as a leading treatment alternative. The competitive landscape features key advancements in immune-oncology drugs. However, Tempest’s unique approach of integrating targets with immune mediation grants it a competitive advantage. The firm continues to evaluate additional large-scale partnerships and further clinical opportunities, seeking to establish a strong position in the global oncology market.
Tempest Therapeutics Buyout
One notable strategy under discussion for Tempest includes potential strategic buyouts or partnerships that could leverage their specialized oncology expertise. While there is no confirmed acquisition as of now, Tempest remains open to negotiations that align with its core objectives and shareholder value maximization.
Tempest Advertising Pvt Ltd
Tempest Advertising, a separate entity from Tempest Therapeutics, is a full-service advertising agency headquartered in Bangalore, India. It serves a wide range of clients across sectors, delivering creative and strategic communication solutions. The firm has carved a niche in the evolving market by emphasizing digital innovation and brand strategy.
Conclusion
Tempest Therapeutics stands as a key player in the biotechnology sector, pioneering advancements in oncology treatments through innovative therapeutic mechanisms. As the company progresses towards late-stage clinical trials, its potential impact on cancer treatment continues to attract attention. The continuous evolution of their pipeline signifies Tempest's commitment to pioneering transformative cancer therapies. Moving forward, Tempest's strategic decisions, including potential buyouts or partnerships, could significantly influence its trajectory and further solidify its standing in the oncology landscape.